Uninformed consent: Mass screening for prostate cancer

Bioethics

Volumn 26, Issue 3, 2012, Pages 143-148

  Justman, Stewart ^a  

^a UNIVERSITY OF MONTANA   (United States)

Author keywords

Harm; Informed consent; Prevention

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLOOD; ETHICS; HEALTH CARE POLICY; HUMAN; INFORMED CONSENT; MALE; MASS SCREENING; PROSTATE TUMOR; UNITED STATES;

HEALTH POLICY; HUMANS; INFORMED CONSENT; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 84856646037     PISSN: 02699702     EISSN: 14678519     Source Type: Journal    
DOI: 10.1111/j.1467-8519.2010.01826.x     Document Type: Article

References (26)

1. A. Barratt et al. Use of Decision Aids to Support Informed Choices about Screening. BMJ 2004; 329: 507.
2. K. Marshall. Prevention. How Much Harm? How Much Benefit? The Ethics of Informed Consent for Preventive Screening Programs. Can Med Assoc J 1996; 155: 382: 'Programs of this nature are experimental, and the appropriate ethical norms for obtaining informed consent should therefore apply'.
3. I. Thompson, M. Resnick & E. Klein. 2001. Prostate Cancer Screening. Totowa, NJ: Humana Press: v.
4. F. Gilliland, W. Hunt & C. Key. Improving Survival for Patients with Prostate Cancer Diagnosed in the Prostate-Specific Antigen Era. Urology 1996; 48: 67.
5. H.G. Welch & P. Albertsen. Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening. J Natl Cancer Inst 2009; 101: 1325-1329.
6. 'Given that the likelihood of being diagnosed with [prostate cancer] is directly related to the rigor with which one looks for it, men who are regularly screened have the most to gain from finasteride in terms of a known health-outcome benefit: a reduced likelihood of being diagnosed with prostate cancer and, consequently, being treated for the disease'
7. H. Parnes et al. Prevention of Hormone-Related Cancers: Prostate Cancer. J Clin Oncol 2005; 23: 374.
8. On the popular belief that screening reduces prostate cancer mortality, see R. Hoffman et al. Prostate Cancer Screening Decisions. Arch Intern Med 2009; 169: 1611-1618.
9. The RCTs are reported in G. Andriole et al. Mortality Results from a Randomized Prostate-Cancer Screening Trial. NEJM 2009; 360: 1310-1319
10. F. Schröder et al. Screening and Prostate-Cancer Mortality in a Randomized European Study. NEJM 2009; 360: 1320-1328. The latter study is the source of the 1400/48/1 statistic.
11. The US Preventive Services Task Force judges the benefits of prostate cancer screening uncertain but the harms it leads to undeniable. See Screening for Prostate Cancer: US. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2008; 149: 185-191.
12. J. Wilson & G. Jungner. 1968. Principles and Practice of Screening for Disease. Geneva: World Health Organization: 26-27.
13. N. Sharifi & B. Kramer. Screening for Prostate Cancer: Current Status and Future Prospects. Am J Med 2007; 120: 743-745.
14. L. Schwartz et al. Enthusiasm for Cancer Screening in the United States. JAMA 2004; 291: 71-78.
15. I. Thompson et al. The Influence of Finasteride on the Development of Prostate Cancer. NEJM 2003; 349: 215-224.
16. A. Wolf et al. The Impact of Informed Consent on Patient Interest in Prostate-Specific Antigen Screening. Arch Intern Med 1996; 156: 1335.
17. M. Litwin & K. Reid. Quality of Life and Health Behavior in Prostate Cancer Screening Populations. In Thompson, Resnick and Klein,
18. D. Vranicar-Lapka et al. Oncology Patients' and Their Significant Others' Responses to a Proposed Cancer Prevention/Detection Program. Cancer Nursing 1992; 15: 47-53.
19. J. Cerhan et al. Family History and Prostate Cancer Risk in a Population-Based Cohort of Iowa Men. Cancer Epidemiology, Biomarkers & Prevention 1999; 8: 58.
20. Moreover, some now recommend that men at 'at risk' of prostate cancer consider taking finasteride - even though the circumstantial association between finasteride and high-grade cancer in the PCPT has not been conclusively cleared up. Inflated baseline risk justifies further risk
21. J. Xu et al. Estimation of Absolute Risk for Prostate Cancer Using Genetic Markers and Family History. Prostate 2009; 69: 1565-1572.
22. E. DeAntoni. Eight Years of 'Prostate Cancer Awareness Week': Lessons in Screening and Early Detection. Cancer 1997; 80: 1845-1851
23. G. Gigerenzer et al. Public Knowledge of Benefits and Breast and Prostate Cancer Screening in Europe. J Natl Cancer I 2009; 101: 1216-1220.
24. B. Kramer et al. Prostate Cancer Screening: What We Know and What We Need to Know. Ann Intern Med 1993; 119: 919, 921.
25. P. Skrabanek. Why is Preventive Medicine Exempted from Ethical Constraints? J Med Ethics 1990; 16: 189.
26. A. Raffle & J. Muir Gray. 2007. Screening: Evidence and Practice. Oxford: Oxford University Press: 249.